Vericel (VCEL) Free Cash Flow Growth (5y) (2015 - 2026)
Vericel (VCEL) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Vericel | 2.33 Bn | 2.18 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.62% |
| Dec 31, 2025 | -25.18% |
| Sep 30, 2025 | 59.46% |
| Jun 30, 2025 | 15.14% |
| Mar 31, 2025 | -31.40% |
| Dec 31, 2024 | 63.45% |
| Sep 30, 2024 | -27.31% |
| Jun 30, 2024 | 63.36% |
| Mar 31, 2024 | -129.01% |
| Dec 31, 2023 | 22.02% |
| Sep 30, 2023 | 46.06% |
| Jun 30, 2023 | 25.94% |
| Mar 31, 2023 | 96.33% |
| Dec 31, 2022 | -38.87% |
| Sep 30, 2022 | 23.36% |
| Jun 30, 2022 | 24.13% |
| Mar 31, 2022 | 16.26% |
| Dec 31, 2021 | 30.12% |
| Sep 30, 2021 | 17.92% |
| Jun 30, 2021 | 16.69% |